Latest Emisphere Tech (EMIS) Headlines Echo T
Post# of 9
Posted On: 03/09/2014 5:53:56 PM
Latest Emisphere Tech (EMIS) Headlines
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024
M2 - Fri Feb 07, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fdknx/oral_proteins_and) has announced the addition of the "Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024" report to their offering. The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. One of the key objectives of this report is to understand the current and future state of the oral proteins and peptide drugs market. This is done by analyzing the following: - Drugs currently available in the market and those under development. - Development and likely sales potential of key marketed and pipeline oral proteins and peptides. - Emerging technologies and key developments supporting the development of improved oral peptide delivery. Key Topics Covered: 1. Executive Summary 1.1. Scope Of The Report 1.2. Research Methodology 1.3. Chapter Outlines 1.4. Key Highlights 1.4.1. Oral Protein And Peptide Market Gained Momentum By The Launch Of Linzess In 2012 1.4.2. Diabetes Dominates The Market 1.4.3. Around 40% Of Molecules Are In The Second Or Higher Phase Of Clinical Development 1.4.4. Sandimmune And Ddavp: Two Oral Peptides Available For More Than A Decade 1.4.5. Gipet And Axcess Are The Most Prominent Technologies 2. Introduction 2.1. Chapter Overview 2.2. Comparison Of Protein / Peptide Drugs With Small Molecule Drugs 2.3. Route Of Administration 2.4. Development Challenges 2.5. Oral Proteins And Peptides 3. Overview And Market Background 4. Drug Profiles And Market Forecast 4.1. Introduction 4.2. Overall Market 4.3. Linaclotide (Linzess / Constella) 4.4. In-105 4.5. Ostora 4.6. Octreolin 4.7. Plecanatide 5. Case Studies: Liprotamase, Sandimmune, Ddavp 5.1. Liprotamase 5.2. Sandimmune 5.3. Ddavp / Minirin (Desmopressin) 6. Technology Platforms 6.1. Chapter Overview 6.2. Gastrointestinal Permeation Enhancement Technology, Gipet (Merrion Pharmaceuticals) 6.3. Eligen (Emisphere Technologies) 6.4. Peptelligence (Enteris Biopharma) 6.5. Oral Antibody Platform (Avaxia Biologics) 6.6. Axcess (Proxima Concepts) 6.7. Multi Matrix System (Cosmo Pharmaceuticals) 6.8. Oramed Pod (Protein Oral Delivery) Technology 7. SWOT Analysis 7.1. Strengths 7.2. Weaknesses 7.3. Opportunities 7.4. Threats 8. Conclusion 8.1. The Rise Of New Technologies 8.2. The Preferred Delivery Mode For A Host Of Indications 8.3. An Emerging Market Close To The Tipping Point 8.4. Challenges Exist, Though These Can Be Surpassed 9. Appendix 1: Tables 10. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/5f...oteins_and
Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended September 30, 2013
GlobeNewswire - Tue Nov 12, 7:01AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended September 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Third Quarter 2013 Earnings Conference Call
GlobeNewswire - Fri Nov 08, 3:15PM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Competitor Analysis Report 2013: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
M2 - Wed Oct 16, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc8nqs/competitor) has announced the addition of the "Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors" report to their offering. Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products. The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. 1st Generation PTH Receptor Agonists 2. Teriparatide Biosimilars 3. PTH-related Proteins/Peptides 4. PTH Variants 5. Nasal Drug Delivery Solutions for rhPTH Receptor Agonists 6. Oral Drug Delivery Solutions for rhPTH Receptor Agonists 7. Transdermal Drug Delivery Solutions for rhPTH Receptor Agonists 8. Corporate PTH Receptor Agonist R&D Pipelines Companies Mentioned - Emisphere Technologies - Intas Biopharmaceuticals - Kyowa Hakko Kirin - KMS Biopharma - Kuros Biosurgery - Lupin Pharmaceuticals - Nitto Denko - Nordic Bioscience - Novartis - NPS Pharmaceuticals - Paras Biopharmaceuticals - Radius Health - Ranbaxy Laboratories - Syneron - Teijin - Uni-Bio Science - USV - Virchow Biotech - Zosano Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/wc8nqs/competitor
OTC Signal Daily Stock Watch - Emisphere Technologies, Inc., (OTC: EMIS)
WorldStockWire - Wed Sep 11, 11:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2013
GlobeNewswire - Tue Aug 13, 7:01AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended June 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Second Quarter 2013 Earnings Conference Call
GlobeNewswire - Thu Aug 08, 4:00PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m8vpx/avitaminosis) has announced the addition of the "Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis). - A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Avitaminosis (Hypovitaminosis) Overview Therapeutics Development An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development Kyowa Hakko Kirin Co Zeria Pharmaceutical Co Emisphere Technologies Cytochroma Inc Avitaminosis (Hypovitaminosis) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/9m...itaminosis
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces First Quarter 2013 Earnings Conference Call
GlobeNewswire - Mon May 13, 5:04PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Novo Nordisk and EMIS Modify Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 01, 3:18PM CDT
Novo Nordisk and Emispher recently modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor against candidates.
Emisphere Technologies Inc amends Oral GLP-1 Development License Agreement with Novo Nordisk
M2 - Tue Apr 30, 7:39AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTC BB:EMIS) said on Monday that it has agreed to amend the Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes using Emisphere's Eligen technology.
Emisphere Announces Restructuring of MHR Obligations
GlobeNewswire - Mon Apr 29, 7:31AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR") to restructure the terms of its obligations under various promissory notes issued to MHR.
Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo Nordisk
GlobeNewswire - Mon Apr 29, 7:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's Eligentechnology (the "Oral GLP-1 Development Agreement").
Genital Herpes - Pipeline Review, H1 2013
M2 - Thu Apr 04, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfc5q6/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2013" report to their offering. 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Emisphere Technologies Inc falls to net loss of USD1.9m in 2012
M2 - Fri Mar 29, 6:17AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTCBB:EMIS) announced on Thursday a net loss of USD1.9m (USD0.03 per basic & diluted share) for the year ended 31 December 2012.
Emisphere Technologies, Inc. Announces Financial Results for Fourth Quarter and Year Ended December 31, 2012
GlobeNewswire - Thu Mar 28, 3:10PM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the fourth quarter and year ended December 31, 2012. The Company plans to host a conference call in the future to provide a Company-wide update on the status of the business.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024
M2 - Fri Feb 07, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fdknx/oral_proteins_and) has announced the addition of the "Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024" report to their offering. The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. One of the key objectives of this report is to understand the current and future state of the oral proteins and peptide drugs market. This is done by analyzing the following: - Drugs currently available in the market and those under development. - Development and likely sales potential of key marketed and pipeline oral proteins and peptides. - Emerging technologies and key developments supporting the development of improved oral peptide delivery. Key Topics Covered: 1. Executive Summary 1.1. Scope Of The Report 1.2. Research Methodology 1.3. Chapter Outlines 1.4. Key Highlights 1.4.1. Oral Protein And Peptide Market Gained Momentum By The Launch Of Linzess In 2012 1.4.2. Diabetes Dominates The Market 1.4.3. Around 40% Of Molecules Are In The Second Or Higher Phase Of Clinical Development 1.4.4. Sandimmune And Ddavp: Two Oral Peptides Available For More Than A Decade 1.4.5. Gipet And Axcess Are The Most Prominent Technologies 2. Introduction 2.1. Chapter Overview 2.2. Comparison Of Protein / Peptide Drugs With Small Molecule Drugs 2.3. Route Of Administration 2.4. Development Challenges 2.5. Oral Proteins And Peptides 3. Overview And Market Background 4. Drug Profiles And Market Forecast 4.1. Introduction 4.2. Overall Market 4.3. Linaclotide (Linzess / Constella) 4.4. In-105 4.5. Ostora 4.6. Octreolin 4.7. Plecanatide 5. Case Studies: Liprotamase, Sandimmune, Ddavp 5.1. Liprotamase 5.2. Sandimmune 5.3. Ddavp / Minirin (Desmopressin) 6. Technology Platforms 6.1. Chapter Overview 6.2. Gastrointestinal Permeation Enhancement Technology, Gipet (Merrion Pharmaceuticals) 6.3. Eligen (Emisphere Technologies) 6.4. Peptelligence (Enteris Biopharma) 6.5. Oral Antibody Platform (Avaxia Biologics) 6.6. Axcess (Proxima Concepts) 6.7. Multi Matrix System (Cosmo Pharmaceuticals) 6.8. Oramed Pod (Protein Oral Delivery) Technology 7. SWOT Analysis 7.1. Strengths 7.2. Weaknesses 7.3. Opportunities 7.4. Threats 8. Conclusion 8.1. The Rise Of New Technologies 8.2. The Preferred Delivery Mode For A Host Of Indications 8.3. An Emerging Market Close To The Tipping Point 8.4. Challenges Exist, Though These Can Be Surpassed 9. Appendix 1: Tables 10. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/5f...oteins_and
Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended September 30, 2013
GlobeNewswire - Tue Nov 12, 7:01AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended September 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Third Quarter 2013 Earnings Conference Call
GlobeNewswire - Fri Nov 08, 3:15PM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Competitor Analysis Report 2013: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
M2 - Wed Oct 16, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc8nqs/competitor) has announced the addition of the "Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors" report to their offering. Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products. The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. 1st Generation PTH Receptor Agonists 2. Teriparatide Biosimilars 3. PTH-related Proteins/Peptides 4. PTH Variants 5. Nasal Drug Delivery Solutions for rhPTH Receptor Agonists 6. Oral Drug Delivery Solutions for rhPTH Receptor Agonists 7. Transdermal Drug Delivery Solutions for rhPTH Receptor Agonists 8. Corporate PTH Receptor Agonist R&D Pipelines Companies Mentioned - Emisphere Technologies - Intas Biopharmaceuticals - Kyowa Hakko Kirin - KMS Biopharma - Kuros Biosurgery - Lupin Pharmaceuticals - Nitto Denko - Nordic Bioscience - Novartis - NPS Pharmaceuticals - Paras Biopharmaceuticals - Radius Health - Ranbaxy Laboratories - Syneron - Teijin - Uni-Bio Science - USV - Virchow Biotech - Zosano Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/wc8nqs/competitor
OTC Signal Daily Stock Watch - Emisphere Technologies, Inc., (OTC: EMIS)
WorldStockWire - Wed Sep 11, 11:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2013
GlobeNewswire - Tue Aug 13, 7:01AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended June 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Second Quarter 2013 Earnings Conference Call
GlobeNewswire - Thu Aug 08, 4:00PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m8vpx/avitaminosis) has announced the addition of the "Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis). - A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Avitaminosis (Hypovitaminosis) Overview Therapeutics Development An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development Kyowa Hakko Kirin Co Zeria Pharmaceutical Co Emisphere Technologies Cytochroma Inc Avitaminosis (Hypovitaminosis) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/9m...itaminosis
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces First Quarter 2013 Earnings Conference Call
GlobeNewswire - Mon May 13, 5:04PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Novo Nordisk and EMIS Modify Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 01, 3:18PM CDT
Novo Nordisk and Emispher recently modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor against candidates.
Emisphere Technologies Inc amends Oral GLP-1 Development License Agreement with Novo Nordisk
M2 - Tue Apr 30, 7:39AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTC BB:EMIS) said on Monday that it has agreed to amend the Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes using Emisphere's Eligen technology.
Emisphere Announces Restructuring of MHR Obligations
GlobeNewswire - Mon Apr 29, 7:31AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR") to restructure the terms of its obligations under various promissory notes issued to MHR.
Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo Nordisk
GlobeNewswire - Mon Apr 29, 7:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's Eligentechnology (the "Oral GLP-1 Development Agreement").
Genital Herpes - Pipeline Review, H1 2013
M2 - Thu Apr 04, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfc5q6/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2013" report to their offering. 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Emisphere Technologies Inc falls to net loss of USD1.9m in 2012
M2 - Fri Mar 29, 6:17AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTCBB:EMIS) announced on Thursday a net loss of USD1.9m (USD0.03 per basic & diluted share) for the year ended 31 December 2012.
Emisphere Technologies, Inc. Announces Financial Results for Fourth Quarter and Year Ended December 31, 2012
GlobeNewswire - Thu Mar 28, 3:10PM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the fourth quarter and year ended December 31, 2012. The Company plans to host a conference call in the future to provide a Company-wide update on the status of the business.
(0)
(0)Emisphere Tech (EMIS) Stock Research Links
Scroll down for more posts ▼